Summary
Thalidomide literally started the improved outlook in MM along with, and followed by Velcade, Revlimid and Stem Cell transplants. To now have increased access in Europe should open up that market eventhough the other agents are in widespread use (I think)
Analysis
I took it for granted that Thalidomide was routinely available in Europe. The fact that it was not means to me that sales will increase dramatically in primary therapy as well as salvage and post transplant maintenance
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
